K2X Technology & Life Science, Inc.

Equities

KBPH

US5015722003

Financial & Commodity Market Operators

Delayed OTC Markets Other stock markets 03:30:56 2022-08-22 pm EDT			5-day change	1st Jan Change
1 ^USD	-45.65%		-.--%	-.--%

2023	FluidAI Medical announced that it has received CAD 15 million in funding from a group of investors	CI
2023	Infinidome Ltd. announced that it has received $9 million in funding from Hanwha Aerospace Co., Ltd., Next Gear Ventures, Honeywell Ventures, VentureIsrael, Kyto Technology and Life Science, Inc., Aston Capital Management and another investor	CI

Kyto Technology and Life Science, Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018

February 12, 2019 at 02:00 pm EST

Kyto Technology and Life Science, Inc. announced earnings results for the third quarter ended December 31, 2018. For the third quarter, the company announced operating loss was USD 57,923 compared to USD 24,133 a year ago. Net loss was USD 57,923 compared to USD 24,133 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. For the nine months, operating loss was USD 156,121 compared to USD 63,862 a year ago. Net loss was USD 156,146 compared to USD 63,862 a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.02 a year ago.

Latest news about K2X Technology & Life Science, Inc.

FluidAI Medical announced that it has received CAD 15 million in funding from a group of investors	23-10-09	CI
Infinidome Ltd. announced that it has received $9 million in funding from Hanwha Aerospace Co., Ltd., Next Gear Ventures, Honeywell Ventures, VentureIsrael, Kyto Technology and Life Science, Inc., Aston Capital Management and another investor	23-04-23	CI
Mrinq Technologies LLP announced that it has received $2.5 million in funding from a group of investors	22-11-09	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-22	CI
Kyto Technology and Life Science, Inc. announced that it has received $2.620875 million in funding	22-02-03	CI
Rhaeos, Inc. announced that it has received $2.2 million in funding from a group of investors	21-12-22	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-18	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2021	21-10-01	CI
Kyto Technology and Life Science, Inc. announced that it has received $0.21 million in funding	21-08-31	CI
Kyto Technology and Life Science, Inc. announced that it has received $0.3 million in funding	21-08-16	CI
Kyto Technology and Life Science, Inc. announced that it has received $0.135 million in funding	21-08-12	CI
Kyto Technology and Life Science, Inc. announced that it has received $0.703 million in funding	21-08-11	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Full Year Ended March 31, 2021	21-08-10	CI
Kyto Technology and Life Science, Inc. Auditor Raises 'Going Concern' Doubt	21-08-09	CI
Single Pass Inc. announced that it has received funding from Kyto Technology and Life Science, Inc., and another investor	21-07-08	CI
AOA Inc. announced that it has received $2.5 million in funding from a group of investors	21-06-27	CI
Kyto Technology and Life Science, Inc. Announces Resignation of Georges Benarroch from the Board of Directors	21-04-12	CI
AOA Inc. announced that it expects to receive $2.5 million in funding	21-02-25	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-16	CI
Kyto Technology and Life Science, Inc. Announces Board Changes	21-01-14	CI
Astrocyte Pharmaceuticals Inc. announced that it has received $7.522677 million in funding from CR Ventures, DeepWork Capital, Trend Investment Group, Kyto Technology and Life Science, Inc. and other investors	20-12-09	CI
Astrocyte Pharmaceuticals Inc. announced that it expects to receive $9.831429 million	20-11-19	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2020	20-11-16	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2020	20-08-04	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Full Year Ended March 31, 2020	20-06-30	CI

Chart K2X Technology & Life Science, Inc.

Duration

Period

Chart K2X Technology & Life Science, Inc.

More charts

Company Profile

Kyto Technology and Life Science, Inc. is an investment company focused on creating an exchange-traded fund (ETF)-like vehicle of diversified and thoroughly vetted start-ups thus defining an entirely new non-correlated asset class. The Companyâs portfolio includes AbFero Pharmaceuticals Inc., Achelios Therapeutics, Inc., Altis Biosystems, AmplifiDX, AOA Inc., Astrocyte Pharmaceuticals Inc. and other.

Sector

Financial & Commodity Market Operators

More about the company

Sector Other Financial & Commodity Market Operators

	1st Jan change	Capi.
K2X TECHNOLOGY & LIFE SCIENCE, INC.	-.--%	16.33M
INTERCONTINENTAL EXCHANGE, INC.	+4.96%	77.41B
HONG KONG EXCHANGES AND CLEARING LIMITED	+6.64%	42.98B
DEUTSCHE BÖRSE AG	+0.27%	37.53B
NASDAQ, INC.	+3.73%	34.7B
B3 S.A. - BRASIL, BOLSA, BALCÃO	-23.99%	12.7B
EURONEXT N.V.	+10.49%	9.65B
MARKETAXESS HOLDINGS INC.	-29.66%	7.76B
TMX GROUP LIMITED	+13.04%	7.34B
SINGAPORE EXCHANGE LIMITED	-5.49%	7.25B

Other Financial & Commodity Market Operators